Chimeric Therapeutics announces new partnership to advance CAR ...

Chimeric Therapeutics (ASX:CHM), a leader in the development of CAR T cell therapies, has entered into a significant partnership with Cell ...

Chimeric Partners with Be The Match BioTherapies to Advance ...

From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin ...

Chimeric announces new collaboration with Achieve Clinics - Biotech

Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a partnership with US-based Achieve that aims to improve patient access to autologous cell ...

Chimeric Therapeutics and OncoBay Clinical Form Partnership to ...

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce that it has entered a strategic ...

Cell Therapies to partner with Chimeric Therapeutics Ltd

Cell Therapies are pleased to announce that they are partnering with Chimeric Therapeutics to explore the potential to manufacture Chimeric's CAR-T assets in ...

Chimeric Therapeutics Announces Capital Raise and Updates

The company is advancing its diversified portfolio of innovative cell therapies, including CAR T and NK cell therapies, which are in various ...

Chimeric and WuXi ATU Partner to Advance CAR-T Pipelines ...

Clinical-stage cell therapy company, Chimeric Theraputics (Chimeric), has announced ... Advanced Therapies (WuXi ATU). The initial five ... new CAR-T ...

Cell Therapies to partner with Chimeric Therapeutics Ltd - LinkedIn

We are thrilled to announce a new partnership between Cell Therapies and Chimeric Therapeutics Ltd! This collaboration marks a significant ...

Chimeric Therapeutics & Oncobay Clinical Form Partnership to ...

Chimeric Therapeutics announce that it has entered a strategic partnership ... Therapeutics & Oncobay Clinical Form Partnership to Advance Chm 1101 (Cltx Car T).

Chimeric enters partnership with WuXi Advanced Therapies

Chimeric Therapeutics will leverage WuXi Advanced Therapies' (WuXi ATU) closed loop CAR T platform and other capabilities to accelerate the clinical ...

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF ...

... the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.

Cell therapy company Chimeric announces collaboration with Cell ...

... Therapies to explore the potential of manufacturing its investigative CAR-T candidates ... “This is great progress for Chimeric and aims to ...

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy ...

BNT211 is BioNTech's most advanced cell therapy development program. BNT211 is an autologous Claudin-6 (CLDN6)-targeting CAR-T cell therapy ...

Carisma Therapeutics Announces Nomination of First In Vivo CAR ...

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ...

AbbVie and Umoja Biopharma Announce Strategic Collaboration to ...

The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This ...

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF ...

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently ...

Chimeric Therapeutics

Chimeric Therapeutics is a results-driven cancer cell therapy company with 3 CAR T & NK cell assets all in Phase 1/1b clinical trials.

Global Roundup: A CAR-T Partnership and CDR-Life Nabs $76M to ...

Australia's Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors.

City of Hope enters licensing agreement with Chimeric to develop its ...

City of Hope enters licensing agreement with Chimeric to develop its pioneering chlorotoxin CAR T cell therapy · DUARTE, Calif. · The therapy is ...

Chimeric Therapeutics Announces FDA Clearance Of IND ...

Chimeric Therapeutics Announces FDA Clearance Of IND Application For CHM 2101, A Novel CDH17 Car T Cell Therapy For Advanced Gastrointestinal ...